

PATENT 267/296 01-0402 (US01)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:	Group Art Unit: 3739
Robert F. Rioux, et al	Confirmation No.: 6134
Serial No.: 10/685,744)
Filed: October 13, 2003	Examiner: Toy, Alex B.
For: LIQUID INFUSION APPARATUS FOR RADIOFREQUENCY TISSUE ABLATION))))

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR § 1.97 and 1.98, the items identified in this Supplemental Information Disclosure Statement ("IDS") are brought to the attention of the Office. Copies of US Patents and US Patent Publications are not enclosed, pursuant to the US Patent & Trademark Office waiver of this requirement under 37 CFR § 1.98 (a)(2)(i) for patent applications filed after June 30, 2003. Copies of other cited references are enclosed.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

03/27/2006 CNEGA1 00000058 501105 10685744 01 FC:1806 160.00 DA

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Services on the date shown below with sufficient postage as "First Class Mail" to addressee in an envelope addressed Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

3/24/06
Date of Deposit

Joselyn L. Lee

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

		S is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1)
		onths of the filing date of the application, which is not a continued prosecution application 53(d) or (2) within three months of entry of the national stage as set forth in 37 CFR §
	v	efore the mailing of a first Office action on the merits; or (4) before the mailing of a first
	• ,	fter filing a request for continued examination under § 1.114. Thus, no fee is required.
		However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR §1.17(p) to the deposit account referenced below.
		However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.
on the : § 1.311	merits, b	OS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action out before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR
		The fee due under 37 CFR § 1.17(p) is submitted herewith.
		A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.
•	or a No ent unde	OS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR office of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A r 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted
		STATEMENT UNDER 37 CFR § 1.97(e):
	Each it	em contained in this IDS was first cited in any communication from a foreign patent office
in a co	unterpar	t foreign application not more than three months prior to the filing of this IDS.
\boxtimes	No iten	n contained in this IDS was cited in a communication from a foreign patent office in a
counte	rpart for	eign application, and, to the knowledge of the person signing this statement after making
reasona	able inqu	uiry, no item of information contained in this IDS was known to any individual designated
in 37 C	CFR 8 1.	56(c) more than three months prior to the filing of this IDS.

PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:

	A check in the amount of is enclosed for the above fee(s).
\boxtimes	Please charge \$180.00 to Deposit Account No. 50-1105 for the above fee(s).
\boxtimes	The Commissioner is authorized to charge any fees required by the filing of these papers, and to
credit a	any overpayment to Vista IP Law Group's Deposit Account No. 50-1105.
	Respectfully submitted,
	VISTA IP LAW GROUP LLP
Dated:	By: March 24, 2006 Michael J. Bolan Reg. No. 42, 330
	Reg. No. 42,339

Customer No. 23410 VISTA IP LAW GROUP LLP 2040 Main Street, 9th Floor Irvine, CA 92614

PTO/SB/08A (07-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Basework Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form: 1449A/PTO

Complete if Known

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

MAR 2 7 2006

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known			
Application Number	10/685,744		
Filing Date	October 14, 2003		
First Named Inventor	Robert F. Rioux		
Art Unit	3739		
Examiner Name	Toy, Alex B.		
Attorney Docket Number	01-0402 (US01)		

	U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Releva Passages or Relevant Figures Appear	
	1.	US-5,279,569	01-18-1994	Neer et al.		
	2.	US-5,456,689	10-10-1995	Kresch et al.		
	3.	US- 5,961,513	10-05-1999	Swanson et al.	-	
	4.	US-6,017,338	01-25-2000	Brucker et al.		
	5.	US- 6,099,526	08-08-2000	Whayne et al.		
	6.	US- 6,235,022	05-22-2001	Hallock et al.		
	7.	US- 6,379,353	04-30-2002	Nichols		
	8.	US- 6,475,213	11-05-2002	Whayne et al.		
	9.	US- 2002/0183638	12-05-2002	Swanson		
		US-				
		US-				
		US-				
		US-				
		US-				
~,		US-				
		US-				
		US-				
		US-				
	1	US-	\- · ·			
		US-				
		US-				
		US-		, and the second		

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Name of Patentee or				Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	т ⁶		
	1.	WO 95/17222	06-29-1995	Angeion Corporation	-			
						•		
				·				

Examiner	 Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(07-05) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

SUPPLEMENTAL . INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet of 1

Complete if Known			
Application Number 10/685,744			
Filing Date	10/14/2003		
First Named Inventor	Robert F. Rioux		
Art Unit	3739		
Examiner Name	Toy, Alex B.		
Attorney Docket Number	01-0402 (US01)		

	NON PATENT LITERATURE DOCUMENTS	,			
Cite No. ¹					
1.	AHMED, Muneeb, MD., et al., "Improved Coagulation with Saline Solution Pretreatment during Radiofrequncy Tumor Ablation in a Canine Model" J. Vasc Interv Radiol 2002; 13: 717-724				
2.	BOEHM, Thomas, M.D., et al., Radio-frequency Tumor Ablation: Internally Cooled Electrode versus Saline- enhanced Technique in an Aggressive Rabbit Tumor-Model® Radilogy 2002; 222: 805-813				
3.	PCT International Search Report for PCT/US2005/000483, Applicant: Scimed Life Systems, Inc., Form PCT/ISA/210 and 220, dated April 14, 2005 (7 pages)				
· 4.	PCT Written Opinion of the International Search Authority for PCT/US2005/000483, Applicant: Scimed Life Systems, Inc., Form PCT/ISA/237, dated April 14, 2005 (4 pages)				
	1. 2.	Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. AHMED, Muneeb, MD., et al., "Improved Coagulation with Saline Solution Pretreatment during Radiofrequncy Tumor Ablation in a Canine Model" J. Vasc Interv Radiol 2002; 13: 717-724 BOEHM, Thomas, M.D., et al., Radio-frequency Tumor Ablation: Internally Cooled Electrode versus Saline-enhanced Technique in an Aggressive Rabbit Tumor-Model" Radilogy 2002; 222: 805-813 PCT International Search Report for PCT/US2005/000483, Applicant: Scimed Life Systems, Inc., Form PCT/ISA/210 and 220, dated April 14, 2005 (7 pages) PCT Written Opinion of the International Search Authority for PCT/US2005/000483, Applicant: Scimed Life Systems, Inc., Form PCT/ISA/237, dated April 14, 2005 (4 pages)			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.